Summary
In this review we will focus on external factors that may modify energy metabolism in human skeletal muscle cells (myotubes) and the ability of the myotubes to switch between lipid and glucose oxidation. We describe the metabolic parameters suppressibility, adaptability and substrate-regulated flexibility and show the influence of nutrients such as fatty acids and glucose (chronic hyperglycemia), and some pharmacological agents modifying nuclear receptors (PPAR and LXR), on these parameters in human myotubes. Possible cellular mechanisms for changes in these parameters will also be highlighted.
Metabolic flexibility
Skeletal muscle is the main tissue involved in lipid and glucose oxidation in the body.
In the postprandial state glucose oxidation dominates, however fat oxidation increases both during fasting and sustained exercise [1] [2] [3] . The ability to switch from predominantly lipid oxidation during fasting conditions to increased glucose oxidation and suppression of lipid oxidation in response to insulin [2, 3] is called metabolic flexibility, and is a characteristic of healthy skeletal muscle [4, 5] . Kelley and Mandarino termed loss of this ability to switch easily between glucose and lipid oxidation metabolic inflexibility [5] . Obesity, insulin resistance and type 2 diabetes (T2D) are linked to reduced lipid oxidation during fasting, impaired postprandial switch from lipid to glucose oxidation and reduced capacity to increase lipid oxidation during exercise [3, [6] [7] [8] . Furthermore, a reduced postprandial switch from lipid to glucose oxidation has been observed in individuals with impaired glucose tolerance [7] , suggesting that inflexibility plays a role in the early development of T2D. The usual way to measure metabolic flexibility to carbohydrate in vivo is to calculate the difference between steady-state respiratory quotient (RQ) at the end of hyperinsulinemic euglycemic clamp and fasting RQ (ΔRQ) [9] . A low RQ indicates high lipid oxidation, whereas a high RQ indicates high glucose oxidation. An impaired ability to increase muscle and whole body glucose oxidation during clamp has been observed in insulin resistant subjects [5, [10] [11] [12] . Additionally, insulinstimulated glucose disposal rate has been found to correlate with metabolic flexibility and to explain most of the variance in ΔRQ [11, 13] , indicating that metabolic flexibility to carbohydrate is primarily reflecting glucose uptake. However, other studies suggest that impairments in substrate uptake and oxidation do not always occur in parallel [1, 14] . Adaptability to lipid, i.e. the capacity to increase lipid oxidation upon increased fatty acid availability, is less thoroughly investigated.
However, Kelley and Simoneau observed a higher postprandial leg RQ in response to a high-fat meal in T2D subjects compared to weight-matched non-diabetic controls [15] .
Metabolic switching of skeletal muscle cells
Metabolic switching of human skeletal muscle cells (myotubes) in vitro has been described by Ukropcova et al. [16] . Suppressibility was defined as the ability of the cells to suppress fatty acid (FA) oxidation by acute addition of glucose, and adaptability was defined as the capacity of the cells to increase FA oxidation upon increased fatty acid availability [16] . In vitro suppressibility was inversely correlated with insulin sensitivity and metabolic flexibility in vivo, whereas adaptability was positively correlated with these parameters [16] . This study indicated that metabolic switching is an intrinsic characteristic of skeletal muscle cells. Stull et al. recently showed that race was a contributor of metabolic flexibility in vivo [13] , signifying that metabolic flexibility is at least partly a product of genetics. Nevertheless, metabolic inflexibility could be due to both intrinsic and extrinsic (induced) factors. Human in vivo studies have shown that postprandial impairments in metabolic flexibility can be improved by weight loss [7, 14, 17] , and that exercise improves the ability of skeletal muscle to oxidize fatty acids during exercise and fasting [14, 18, 19] . A recent intervention study on men with metabolic syndrome indicated that isoenergetic modulation of dietary fat quality and quantity did not affect respiratory quotient or carbohydrate and lipid oxidation during fasting or after a meal [20] . However, the sample size in this study was relatively small for detecting such changes. The investigation of substrate oxidation started decades ago, and according to Randle cycle [21] , fatty acids reduce glucose oxidation, whereas glucose reduces fatty acid oxidation through "reverse Randle cycle" [22, 23] . While the mechanistic basis for Randle cycle is relatively well understood, the molecular mechanism underlying metabolic inflexibility remains to be revealed.
Methodology used to measure metabolic switching of human myotubes
For a better description of metabolic switching in cells, we have used three parameters, the two parameters suppressibility and adaptability as introduced by Ukropcova [16] , and the new parameter substrate-regulated flexibility [24] in functional studies of fuel selection and energy metabolism in cell cultures. Substrateregulated flexibility was defined as the ability to increase fatty acid (FA) oxidation when changing from a high glucose (5 mM), low FA (5 µM) condition ("fed") to a high FA (100 µM), low glucose (0 mM) ("fasted") condition (Figure 1 ).
The suppressibility of oleic acid (OA) oxidation, measured as carbondioxide formation (CO 2 ), when 5 mM glucose was added acutely to the cells, was independent of the fatty acid concentration in the range from 5 to 300 µM ( Figure 2A ). Moreover, it was observed that maximum suppression by about 50 % was reached at 2-5 mM glucose, and already at 0.5-1 mM glucose acutely we observed a significant reduction in OA oxidation (IC 50 0.55 mM). Moreover, we also showed that suppressibility of OA oxidation by glucose was not affected when increasing mitochondrial respiration by addition of the mitochondrial uncoupler 2.4-dinitrophenol (DNP) ( Figure 2B ). In the opposite situation, suppressibility of glucose oxidation by acute addition of OA was strongly dependent of mitochondrial respiration ( Figure 2B ) probably because glycolytic metabolism is preferred in human myotubes [25, 26] .
The adaptability of OA oxidation in the range from 5 to 300 µM of the fatty acid is shown in Figure 2C , which demonstrate that the adaptability was dependent on FA concentration. For our calculations of this parameter we have mostly used the ratio 100 µM FA/ 5 µM FA (Figure 1 ).
Addition of insulin (100 nM) to the low FA condition ("fed") condition did not change substrate-regulated flexibility, probably because most of the glucose uptake in human myotubes occurs independent of insulin. Moreover, Ukropcova et al. [16] observed that insulin was not needed for the expression of the metabolic switching phenotype in muscle cells. We also found that this parameter was robust against varying degree of fatty acid uptake by the cells (data not shown). The details about muscle cell cultures used in these studies are given in the legend to . However, the adaptability of OA oxidation was not affected after chronic HG treatment [26] . We also measured substrate-regulated flexibility, which was significantly reduced after HG treatment of the cells ( Figure 5 ).
Metabolic switching of human myotubes can be modified by agonist regulating the nuclear receptors PPARs and LXRs
In addition to various FAs and chronic hyperglycemia, we also examined the possible involvement of peroxisome proliferator-activated receptors (PPARs) and liver X receptors (LXRs) in metabolic switching. The myotubes were incubated for 4 days with compounds known to act agonistic at these receptors.
PPARs are activated by fatty acids and therefore act as lipid sensors in the body [29] [30] [31] . Three subtypes of PPARs have been identified, differing in tissue distribution and function. PPARα is predominantly expressed in the liver, but also found in heart and skeletal muscle, where it increases fatty acid oxidation [29, [32] [33] [34] . PPARγ is mainly expressed in adipose tissue, and plays an important role in adipocyte differentiation and lipid storage [31, [35] [36] [37] . In contrast to the other subtypes, PPARδ (also called PPARβ) is ubiquitously expressed and is relatively abundant in skeletal muscle [38] . The human myotube model used in our experiments express more PPARδ than PPARα (unpublished observations).
The role of PPARδ is currently under investigation, and is so far found to increase fatty acid oxidation in skeletal muscle [39] , and might thus play an important role in energy turnover [40] . Treatment of the myotubes with the PPARδ agonists GW501516 and the pan-agonist TTA for 4 days during differentiation increased CO 2 formation from the cells when incubated acutely with labelled OA (Figure 6 ). The two metabolic parameters suppressibility and adaptability were not changed by PPAR activation, but substrate-regulated flexibility was 2-fold increased by TTA (Figure 7 ), but not by GW501516. TTA is a pan-PPAR activator that reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents [41] . Dual and pan-PPAR agonists are currently being developed for treatment of type 2 diabetes (T2D) [42] , and TTA has been shown to improve glucose metabolism in insulin-resistant rats [43] and to stimulate mitochondrial proliferation in rat skeletal muscle [44] . Recently, we have shown that preincubation of myotubes with TTA enhanced mitochondrial fatty acid and glucose oxidation, indicating increased mitochondrial biogenesis and an improved glucose metabolism [27] . At the same time TTA opposed increased lipid accumulation by the cells. TTA seems more potent in activating rat PPARα than PPARδ [43, 45] , whereas the opposite has been demonstrated for human PPARs [46] .
This may partly explain why TTA has particularly strong effects on hepatic metabolism in rodents where PPARα is a major regulator, but relatively modest effects in skeletal muscle where PPARδ may play a more prominent role [38, 47] . In human myotubes, PPARδ seems to play a dominant role over PPARα in controlling lipid oxidation [48] , and we have demonstrated that preincubation of myotubes with the PPARδ selective agonist GW501516 and TTA, but not the PPARα-selective agonists fenofibrate and clofibrate (at PPARα-selective concentrations), could induce increased mitochondrial fatty acid oxidation in myotubes [49] . Our data on fatty acid oxidation ( Figure 6 ) also demonstrate that an increased capacity for oxidation of fatty acids (increased CO 2 formation) alone is not sufficient to change the metabolic parameters described in this paper.
LXRs play a crucial role in regulation of cholesterol, lipid and carbohydrate metabolism [50] [51] [52] [53] [54] . We have shown that chronic activation of LXRs may affect glucose uptake and oxidation as well as promote a strong effect on lipid metabolism by increasing fatty acid uptake and accumulation as complex lipids and to stimulate lipogenesis in human myotubes [55, 56] . Thus, LXRs could play a role in the regulation of metabolic switching. We have shown that treatment of myotubes with the LXR agonist T0901317 for 2 days did not affect suppressibility or adaptability of the cells per se, but counteracted the effect of EPA on these two parameters ( Figure   8A and B, [24] ). Treatment with T0901317 did not change substrate-regulated flexibility, nor cancel out the effect of EPA on this parameter. Therefore, LXRs do not seem to play a major role, but show some impact on metabolic switching of myotubes.
Possible mechanisms for changes in metabolic switching of myotubes
To study whether the effects of FA pretreatment on metabolic switching could be due to altered gene expression, microarray analysis was performed [24] . This revealed that 24 h treatment with 0.1 mM EPA regulated more genes than the other ( Figure 9 ). In vivo studies (both human and animal) have shown that fatty acid oxidation and the activity of β-oxidation enzymes are increased in skeletal muscle of individuals/rats fed a high-fat diet [57] [58] [59] . This could be a mechanism to compensate for elevated availability of fatty acids to protect against lipid accumulation, and might be reflected in vitro by the adaptability parameter.
Chronic treatment with the PPARδ agonist GW501516 markedly increased OA oxidation and this substance has previously been shown to induce genes involved in fatty acid transport and oxidation in cells [39, 48, 60] , and to increase fatty acid oxidation [61, 62] . Moreover, we demonstrate that increasing the capacities for fatty acid oxidation by PPAR activation, or respiration by mitochondrial uncoupling did not change the metabolic parameters in the myotubes. The pan-PPAR agonist TTA also increased fatty acid oxidation, but in contrast to GW501516 it seemed to increase substrate-regulated flexibility. We have previously shown that TTA also positively influences glucose metabolism in myotubes [27] , and this fatty acid analogue also increased adaptability after 24 h pretreatment ( Figure 4B ). Thus, TTA may show PPAR and PPAR-independent effects [41, 45] membrane potential, as well as resulted in smaller and more compact mitochondria with no effect on mitochondrial DNA [80] . Another mechanism by which HG theoretically could affect metabolism is through altered AMPK activity, since glucose infusion in rats has been shown to reduce phosphorylation of AMPK and its substrate acetyl-CoA carboxylase (ACC) in red but not white muscle [81] . In our study [26] , AMPK activity could not explain the metabolic impairments because phosphorylation of AMPK and ACC was not changed after HG exposure. Taken together, chronic HG impaired metabolic switching of myotubes probably due to an induced mitochondrial dysfunction.
Conclusion
The in vitro metabolic parameters suppressibility, adaptability and substrate-regulated Substrate-regulated flexibility: the ability to increase the OA oxidation while changing from the "fed" (low fatty acid, high glucose) to the "fasted" (high fatty acid, no glucose added) condition: [oxidation of 100 µM OA without glucose added/ oxidation of 5 µM OA at 5 mM glucose]. 
